Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study.
about
Interventions for basal cell carcinoma of the skinNonsurgical innovations in the treatment of nonmelanoma skin cancerAdvances in the use of topical imiquimod to treat dermatologic disordersBasal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical TherapiesImiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonistsThe effective treatment of basal cell carcinoma.Depigmentation therapies for normal skin in vitiligo universalis.Imiquimod as a dermatological therapy.Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in miceThe pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.Roles of TLR7 in activation of NF-κB signaling of keratinocytes by imiquimod.Imiquimod induces apoptosis of squamous cell carcinoma (SCC) cells via regulation of A20.The imidazoquinolines and their place in the therapy of cutaneous disease.Current treatment patterns in non-melanoma skin cancer across Europe.Summary of actinic keratosis studies with imiquimod 5% cream.The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview.A review of imiquimod 5% cream for the treatment of various dermatological conditions.Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.Advances in the management of basal cell carcinoma.Squamous cell carcinoma in situ of the skin: history, presentation, biology and treatment.Interventions for basal cell carcinoma of the skin: systematic review.Bowen's Disease Treated with Imiquimod and CryotherapyMolecular aetiology and pathogenesis of basal cell carcinoma.Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas.Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein.Current modalities and new advances in the treatment of basal cell carcinoma.Clinical variants, stages, and management of basal cell carcinoma.Risk of nonmelanoma skin cancer with azathioprine use.Guidelines for the management of basal cell carcinoma.Use of imiquimod 5% cream (Aldara) in cats with multicentric squamous cell carcinoma in situ: 12 cases (2002-2005).Treating skin cancer with topical cream.Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: a case series and review.Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials.Medical approaches to non-melanoma skin cancer.Toll-like receptors and skin cancer.A Network Meta-Analysis of Non-Melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment.Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.
P2860
Q24246327-1203DE82-895E-4787-8998-78086D39122FQ24632006-24BC14D4-2EAE-41DB-86F7-DB50F0CCE8E3Q24647413-D00BACCB-499B-4342-B4AB-FF5C5E2A6ADFQ26744173-1DC1DB65-9B9F-4F5D-9C5E-9A2087285636Q33293591-89FE4C17-D880-455B-98F6-3056816857C9Q33302568-256DFE9C-A47C-4AB6-94E5-CB63B791491DQ33423843-3664A263-9300-4BEB-B24D-A834454B2E29Q33739817-D58E1B98-2166-4E13-AD1A-B8BF350471F0Q34546035-3301D821-55DD-4490-9638-30006CA85ED6Q34794683-4878A95F-26B7-4B5C-A8DE-98B0DDDAD077Q35018021-085CB0D5-F869-4C3A-8695-0AAFDD5B4EC5Q35023079-B34DF6C5-63F4-446F-9FF4-E954C78478FAQ35151677-6C3BA070-5B7F-4008-B606-DEC677001A41Q35164704-90122FB3-C20A-4E06-9128-C2FA26D45A3FQ35548847-BF717536-8981-48C4-A4EB-C84647F2DE5BQ35583162-7080C06F-B12B-43EE-9C5F-6A85F64E02BCQ35583168-8E388722-9B7D-4BD3-B0E1-A4523B944F13Q35583358-9DFF844E-7278-4A6B-BAF3-60F7F33D10DAQ35632513-A593E836-8CB9-45E2-867C-BEE4EFCD47E4Q35659377-53355DFE-98E9-4FE1-A7EB-6648B4A0D3E5Q35666541-1B17BB01-EBBC-47B5-A5AA-1FA7C0734CD0Q35886161-95D84D56-EA66-4931-A745-84DD041D4A32Q36021174-1187F869-5FA3-4C64-9D21-8EC47B063CE5Q36158929-FEDDDCAF-CC2E-46D3-ADF7-6E47402A5D56Q36362591-9215D6C4-83C9-43F8-818D-5AF4B5C47E24Q36373370-C45EFE80-1C6E-4C3C-9AFB-2AE2769E532AQ36402362-78BD7FA7-17FB-4304-8900-C1CBD6087346Q36478773-3956A041-29D9-455A-8FA7-9DE10041E182Q36612692-E768DFF5-EB42-4BDA-84C6-42BECFF26D22Q37126243-2AFEC0E3-3C3E-463A-8EE7-8EE6088F8E19Q37204336-41B980A9-4794-45B8-9721-162391C4C0A5Q37380110-9C060870-476A-4702-A914-A580AFFE276EQ37735187-8C6BE95C-1B56-46B8-947D-978EC6C71CAAQ37903872-86B52EB9-7083-4986-9E51-01DF997AC465Q38011775-5232FABF-69FD-4F6E-B4C3-763296A15411Q38162923-1788A942-D13A-4B09-B67B-F534F7286199Q38205438-B917C401-A98B-405F-8682-2228C265582BQ38859587-3FAB270B-EFBA-4941-B810-A223E20EC667Q38947206-FDB83EC3-79D4-4ABF-9FE1-39461D129F6BQ39216546-CDAE482F-068A-4947-9818-BF96BC807D9A
P2860
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Imiquimod 5% cream for the tre ...... zed, vehicle-controlled study.
@en
Imiquimod 5% cream for the tre ...... zed, vehicle-controlled study.
@nl
type
label
Imiquimod 5% cream for the tre ...... zed, vehicle-controlled study.
@en
Imiquimod 5% cream for the tre ...... zed, vehicle-controlled study.
@nl
prefLabel
Imiquimod 5% cream for the tre ...... zed, vehicle-controlled study.
@en
Imiquimod 5% cream for the tre ...... zed, vehicle-controlled study.
@nl
P2093
P356
P1476
Imiquimod 5% cream for the tre ...... zed, vehicle-controlled study.
@en
P2093
Amit Pandya
Angie Ginkel
John K Geisse
Kara Andres
Kenneth Gross
Mary Owens
Phoebe Rich
P304
P356
10.1067/MJD.2002.126215
P407
P577
2002-09-01T00:00:00Z